Curagen ponders sale in a "difficult funding environment"
This article was originally published in Scrip
Executive Summary
Curagen will consider buy-out offers as part of a strategic review in what it describes as "a difficult external funding environment". The company will mull over several alternatives to increase shareholder value, including a deal for its anticancer CR011, acquiring new products, or selling the business.